Pliant Therapeutics
PLRX
136 hedge funds and large institutions have $1.04B invested in Pliant Therapeutics in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 34 reducing their positions, and 27 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 34
47% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $1.96M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
2.39% more ownership
Funds ownership: 98.17% → 100.55% (+2.4%)
1% less capital invested
Capital invested by funds: $1.05B → $1.04B (-$9.48M)
5% less funds holding
Funds holding: 143 → 136 (-7)
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$25.1M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$19.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.6M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.45M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16.6M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.26M |
| 3 |
D.E. Shaw & Co
New York
|
-$6.41M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.29M |
| 5 |
Two Sigma Investments
New York
|
-$3.75M |
PLRX Hedge Fund Activity: Q3 2023 in Review
136 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2023, worth a combined $1.04B — down 0.9% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PLRX and 21 opened new positions — a net loss of 6 holders — while 34 trimmed existing stakes and 51 added.
The largest buyer was Deep Track Capital, adding an estimated $25.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $16.6M sold.
- 136 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2023, down from 143 in Q2 2023.
- Funds reported $1.04B of Pliant Therapeutics stock for Q3 2023, down 0.9% quarter-over-quarter.
- 21 funds opened new Pliant Therapeutics positions in Q3 2023 and 27 closed out, a net change of -6 holders.
- The largest Pliant Therapeutics buyer in Q3 2023 was Deep Track Capital, an estimated $25.1M added.
- The largest Pliant Therapeutics seller in Q3 2023 was Avidity Partners Management, an estimated $16.6M sold.
Based on aggregated 13F filings for Q3 2023.